SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
In this photo illustration, Eliquis, one of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. is made available to customers at the New City Halsted Pharmacy on August 29, 2023, in Chicago, Illinois.
The judge said plaintiff the Chamber of Commerce "demonstrated neither a strong likelihood of success nor irreparable harm."
A federal judge in Ohio on Friday blocked an attempt by corporate interests to stop Medicare's historic negotiation of certain drug prices with pharmaceuticals.
Medicare gained the power to negotiate drug prices as part of the Inflation Reduction Act (IRA), but the several industry groups and drug makers have sued to forestall the program, arguing that it is unconstitutional, CNN explained. One of those groups was the U.S. Chamber of Commerce, which filed its lawsuit in June. The Ohio judge Friday rejected its request for a preliminary injunction to block the program before October 1, the date by which pharmaceuticals must agree to negotiate or not.
"This is the first major blow to Big Pharma in its legal battles to block the drug price negotiation provisions under the Inflation Reduction Act," Peter Maybarduk, director of the Access to Medicines program at Public Citizen, said in a statement.
"The Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
"The Chamber’s lawsuit lacks merit," Maybarduk contined. "The court made the right decision not to grant the injunction, which would have caused needless patient suffering and treatment rationing."
Judge Michael Newman of the Southern District of Ohio, a Trump appointee, ruled that the chamber "demonstrated neither a strong likelihood of success nor irreparable harm," as CNBC reported.
"Consequently, their request for immediate preliminary injunctive relief... is denied," Newman concluded.
Newman also rejected the Biden administration's request to dismiss the case. Instead, he gave the Chamber of Commerce until October 13 to answer some questions about its argument and the administration until October 27 to renew its motion to dismiss.
While the chamber had argued the negotiation program was unconstitutional for multiple reasons, Newman pointed out that drug companies are not forced to participate in Medicare.
"As there is no constitutional right (or requirement) to engage in business with the government, the consequences of that participation cannot be considered a constitutional violation," he said.
The Biden administration celebrated the news.
"Today’s ruling from the Southern District of Ohio affirms that Medicare will move forward with negotiating lower prices for millions of seniors," Press Secretary Karine Jean-Pierre said in a statement. "And, the Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
The administration announced the first 10 drugs to be subject to negotiations in August. They included the blood-clot treatment Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and several Novo Nordisk insulins, according to CNN.
With the injunction blocked, "drug companies should agree to participate in the negotiation program in good faith," Maybarduk said. "The program is an important first step in ending the exorbitant prices charged to Medicare enrollees. It’s time for Big Pharma to drop their lawsuits and drop their prices.”
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
A federal judge in Ohio on Friday blocked an attempt by corporate interests to stop Medicare's historic negotiation of certain drug prices with pharmaceuticals.
Medicare gained the power to negotiate drug prices as part of the Inflation Reduction Act (IRA), but the several industry groups and drug makers have sued to forestall the program, arguing that it is unconstitutional, CNN explained. One of those groups was the U.S. Chamber of Commerce, which filed its lawsuit in June. The Ohio judge Friday rejected its request for a preliminary injunction to block the program before October 1, the date by which pharmaceuticals must agree to negotiate or not.
"This is the first major blow to Big Pharma in its legal battles to block the drug price negotiation provisions under the Inflation Reduction Act," Peter Maybarduk, director of the Access to Medicines program at Public Citizen, said in a statement.
"The Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
"The Chamber’s lawsuit lacks merit," Maybarduk contined. "The court made the right decision not to grant the injunction, which would have caused needless patient suffering and treatment rationing."
Judge Michael Newman of the Southern District of Ohio, a Trump appointee, ruled that the chamber "demonstrated neither a strong likelihood of success nor irreparable harm," as CNBC reported.
"Consequently, their request for immediate preliminary injunctive relief... is denied," Newman concluded.
Newman also rejected the Biden administration's request to dismiss the case. Instead, he gave the Chamber of Commerce until October 13 to answer some questions about its argument and the administration until October 27 to renew its motion to dismiss.
While the chamber had argued the negotiation program was unconstitutional for multiple reasons, Newman pointed out that drug companies are not forced to participate in Medicare.
"As there is no constitutional right (or requirement) to engage in business with the government, the consequences of that participation cannot be considered a constitutional violation," he said.
The Biden administration celebrated the news.
"Today’s ruling from the Southern District of Ohio affirms that Medicare will move forward with negotiating lower prices for millions of seniors," Press Secretary Karine Jean-Pierre said in a statement. "And, the Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
The administration announced the first 10 drugs to be subject to negotiations in August. They included the blood-clot treatment Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and several Novo Nordisk insulins, according to CNN.
With the injunction blocked, "drug companies should agree to participate in the negotiation program in good faith," Maybarduk said. "The program is an important first step in ending the exorbitant prices charged to Medicare enrollees. It’s time for Big Pharma to drop their lawsuits and drop their prices.”
A federal judge in Ohio on Friday blocked an attempt by corporate interests to stop Medicare's historic negotiation of certain drug prices with pharmaceuticals.
Medicare gained the power to negotiate drug prices as part of the Inflation Reduction Act (IRA), but the several industry groups and drug makers have sued to forestall the program, arguing that it is unconstitutional, CNN explained. One of those groups was the U.S. Chamber of Commerce, which filed its lawsuit in June. The Ohio judge Friday rejected its request for a preliminary injunction to block the program before October 1, the date by which pharmaceuticals must agree to negotiate or not.
"This is the first major blow to Big Pharma in its legal battles to block the drug price negotiation provisions under the Inflation Reduction Act," Peter Maybarduk, director of the Access to Medicines program at Public Citizen, said in a statement.
"The Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
"The Chamber’s lawsuit lacks merit," Maybarduk contined. "The court made the right decision not to grant the injunction, which would have caused needless patient suffering and treatment rationing."
Judge Michael Newman of the Southern District of Ohio, a Trump appointee, ruled that the chamber "demonstrated neither a strong likelihood of success nor irreparable harm," as CNBC reported.
"Consequently, their request for immediate preliminary injunctive relief... is denied," Newman concluded.
Newman also rejected the Biden administration's request to dismiss the case. Instead, he gave the Chamber of Commerce until October 13 to answer some questions about its argument and the administration until October 27 to renew its motion to dismiss.
While the chamber had argued the negotiation program was unconstitutional for multiple reasons, Newman pointed out that drug companies are not forced to participate in Medicare.
"As there is no constitutional right (or requirement) to engage in business with the government, the consequences of that participation cannot be considered a constitutional violation," he said.
The Biden administration celebrated the news.
"Today’s ruling from the Southern District of Ohio affirms that Medicare will move forward with negotiating lower prices for millions of seniors," Press Secretary Karine Jean-Pierre said in a statement. "And, the Biden-Harris Administration won’t stop fighting for what we know to be true: that nothing in the Constitution prohibits Medicare from negotiating drug prices."
The administration announced the first 10 drugs to be subject to negotiations in August. They included the blood-clot treatment Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and several Novo Nordisk insulins, according to CNN.
With the injunction blocked, "drug companies should agree to participate in the negotiation program in good faith," Maybarduk said. "The program is an important first step in ending the exorbitant prices charged to Medicare enrollees. It’s time for Big Pharma to drop their lawsuits and drop their prices.”